ABUS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Arbutus Biopharma Corp (ABUS) is not a strong buy for a beginner, long-term investor at this time. Despite some positive technical indicators and a favorable analyst rating, the company's weak financial performance, lack of significant trading trends, and potential downside in the stock trend suggest a cautious approach. Holding the stock may be more prudent until clearer positive catalysts emerge.
The technical indicators show a bullish trend with MACD positively expanding, RSI in the neutral zone (61.531), and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 4.275), with potential upside to R2: 4.445. However, the stock trend analysis indicates a 70% chance of declining in the short term (-0.88% next day, -1.54% next week, -5.24% next month).
Bullish technical indicators (MACD, moving averages).
Analyst Buy rating from Jefferies.
Favorable legal developments in patent litigation against Moderna (dismissal of two key defenses).
Weak financial performance in Q3 2025 with significant YoY declines in revenue (-60.49%), net income (-60.73%), and EPS (-60.00%).
No significant hedge fund or insider trading activity.
Stock trend analysis indicates a high probability of short-term decline.
No recent Congress trading data or significant political/influential figure activity.
The company's Q3 2025 financial performance was weak, with revenue dropping to $529,000 (-60.49% YoY), net income declining to -$7,742,000 (-60.73% YoY), and EPS falling to -0.04 (-60.00% YoY). Gross margin remained steady at 100%.
Jefferies analyst Dennis Ding maintains a Buy rating on ABUS, citing confidence in the company's patent position against Moderna. However, the analyst notes that Arbutus faces challenges in proving infringement under the 'doctrine of equivalents,' which could complicate the litigation outcome.
